$KPTI
Karyopharm Therapeutics Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024091210 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $38.78M $42.79M
YoY Change 7.7% 13.86%
Cost Of Revenue $1.300M $1.465M
YoY Change 44.44% 22.7%
Gross Profit $37.48M $41.32M
YoY Change 6.79% 13.57%
Gross Profit Margin 96.65% 96.58%
Selling, General & Admin $27.63M $31.07M
YoY Change -10.3% -9.89%
% of Gross Profit 73.72% 75.19%
Research & Development $36.13M $38.37M
YoY Change 1.63% 21.9%
% of Gross Profit 96.4% 92.86%
Depreciation & Amortization $83.00K $91.00K
YoY Change 3.75% 9.64%
% of Gross Profit 0.22% 0.22%
Operating Expenses $65.07M $70.91M
YoY Change -3.27% 7.5%
Operating Profit -$26.28M -$28.12M
YoY Change -15.92% -4.91%
Interest Expense -$9.553M $8.949M
YoY Change -257.3% -402.33%
% of Operating Profit
Other Income/Expense, Net -$5.761M $51.98M
YoY Change 78.14% 173163.33%
Pretax Income -$32.04M $23.86M
YoY Change -7.1% -173.41%
Income Tax $28.00K $67.00K
% Of Pretax Income 0.28%
Net Earnings -$32.07M $23.79M
YoY Change -7.05% -172.91%
Net Earnings / Revenue -82.7% 55.61%
Basic Earnings Per Share -$0.26 $0.15
Diluted Earnings Per Share -$0.26 -$0.20
COMMON SHARES
Basic Shares Outstanding 124.7M 117.7M
Diluted Shares Outstanding 125.0K 154.4M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $133.5M $152.1M
YoY Change -35.9% -35.75%
Cash & Equivalents $72.83M $84.77M
Short-Term Investments $60.70M $67.35M
Other Short-Term Assets $14.78M $14.95M
YoY Change 7.09% -19.93%
Inventory $4.672M $3.476M
Prepaid Expenses
Receivables $31.78M $38.00M
Other Receivables $0.00 $0.00
Total Short-Term Assets $184.8M $208.5M
YoY Change -29.81% -28.43%
LONG-TERM ASSETS
Property, Plant & Equipment $495.0K $628.0K
YoY Change -27.84% -89.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.640M $1.638M
YoY Change 26.15% 323.26%
Total Long-Term Assets $4.721M $5.437M
YoY Change -29.93% -15.69%
TOTAL ASSETS
Total Short-Term Assets $184.8M $208.5M
Total Long-Term Assets $4.721M $5.437M
Total Assets $189.5M $214.0M
YoY Change -29.81% -28.15%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.783M $2.797M
YoY Change 513.26% 22.3%
Accrued Expenses $50.11M $49.81M
YoY Change -10.07% -9.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.49M $57.62M
YoY Change -0.94% -2.22%
LONG-TERM LIABILITIES
Long-Term Debt $264.1M $264.6M
YoY Change -12.9% -12.73%
Other Long-Term Liabilities $6.184M $4.281M
YoY Change 333.05% -38.27%
Total Long-Term Liabilities $6.184M $4.281M
YoY Change 333.05% -98.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.49M $57.62M
Total Long-Term Liabilities $6.184M $4.281M
Total Liabilities $349.1M $346.1M
YoY Change -5.73% -6.22%
SHAREHOLDERS EQUITY
Retained Earnings -$1.500B -$1.501B
YoY Change 3.79% 6.37%
Common Stock $1.373B $1.369B
YoY Change 2.06% 2.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$159.6M -$132.1M
YoY Change
Total Liabilities & Shareholders Equity $189.5M $214.0M
YoY Change -29.81% -28.15%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$32.07M $23.79M
YoY Change -7.05% -172.91%
Depreciation, Depletion And Amortization $83.00K $91.00K
YoY Change 3.75% 9.64%
Cash From Operating Activities -$19.45M -$38.50M
YoY Change -34.12% 49.81%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $7.474M $51.26M
YoY Change -197.32% 142.14%
Cash From Investing Activities $7.474M $51.26M
YoY Change -197.32% 142.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 40.97M
YoY Change 4663.49%
NET CHANGE
Cash From Operating Activities -19.45M -38.50M
Cash From Investing Activities 7.474M 51.26M
Cash From Financing Activities 0.000 40.97M
Net Change In Cash -11.98M 53.73M
YoY Change -67.81% -1564.83%
FREE CASH FLOW
Cash From Operating Activities -$19.45M -$38.50M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$19.45M -$38.50M
YoY Change -34.12% 49.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36167
dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
658-0600
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KPTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
124683681
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84774000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52231000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
67350000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
139212000
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
37995000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
26962000
CY2024Q2 us-gaap Inventory Net
InventoryNet
3476000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3043000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14913000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11813000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
32000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
660000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
208540000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
233921000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
628000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
606000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3171000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4276000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
304000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
301000
CY2024Q2 us-gaap Other Assets
OtherAssets
1334000
CY2023Q4 us-gaap Other Assets
OtherAssets
1334000
CY2024Q2 us-gaap Assets
Assets
213977000
CY2023Q4 us-gaap Assets
Assets
240438000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2797000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3123000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49809000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61394000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3545000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3308000
CY2024Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1468000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1654000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
57619000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
69479000
CY2024Q2 kpti Convertible Senior Notes Due Two Thousand Twenty Five
ConvertibleSeniorNotesDueTwoThousandTwentyFive
24359000
CY2023Q4 kpti Convertible Senior Notes Due Two Thousand Twenty Five
ConvertibleSeniorNotesDueTwoThousandTwentyFive
170919000
CY2024Q2 kpti Convertible Senior Notes Due Two Thousand Twenty Nine
ConvertibleSeniorNotesDueTwoThousandTwentyNine
73255000
CY2023Q4 kpti Convertible Senior Notes Due Two Thousand Twenty Nine
ConvertibleSeniorNotesDueTwoThousandTwentyNine
0
CY2024Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
93517000
CY2023Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
0
CY2024Q2 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
73499000
CY2023Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132479000
CY2024Q2 kpti Common Stock Warrants
CommonStockWarrants
18632000
CY2023Q4 kpti Common Stock Warrants
CommonStockWarrants
0
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
955000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2789000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4281000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
978000
CY2024Q2 us-gaap Liabilities
Liabilities
346117000
CY2023Q4 us-gaap Liabilities
Liabilities
376644000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
124635000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
124635000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114915000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114915000
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
13000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1369060000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1350981000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-605000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-161000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1500608000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1487038000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-132140000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-136206000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
213977000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240438000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42786000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37579000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75912000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76277000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
38371000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31477000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73796000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63816000
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
31070000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34481000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
60619000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
70388000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
70906000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
67152000
us-gaap Operating Expenses
OperatingExpenses
137791000
us-gaap Operating Expenses
OperatingExpenses
136749000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-28120000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29573000
us-gaap Operating Income Loss
OperatingIncomeLoss
-61879000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60472000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1930000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2824000
us-gaap Investment Income Interest
InvestmentIncomeInterest
4086000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5673000
CY2024Q2 us-gaap Interest Expense
InterestExpense
8949000
CY2023Q2 us-gaap Interest Expense
InterestExpense
5784000
us-gaap Interest Expense
InterestExpense
14833000
us-gaap Interest Expense
InterestExpense
11542000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14296000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14492000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
51979000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2930000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
48447000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6103000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
23859000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32503000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13432000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66575000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
67000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
127000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
138000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
23792000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
us-gaap Net Income Loss
NetIncomeLoss
-13570000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121027000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114207000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118240000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113846000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154425000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114207000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127066000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113846000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
23792000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
us-gaap Net Income Loss
NetIncomeLoss
-13570000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-297000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-264000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-395000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23705000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32994000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14014000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66901000
us-gaap Profit Loss
ProfitLoss
-13570000
us-gaap Profit Loss
ProfitLoss
-66756000
us-gaap Share Based Compensation
ShareBasedCompensation
10380000
us-gaap Share Based Compensation
ShareBasedCompensation
11449000
us-gaap Depreciation
Depreciation
176000
us-gaap Depreciation
Depreciation
373000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1605000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
392000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1581000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2141000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
14342000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11033000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14806000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
433000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-552000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3100000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1724000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-1105000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-942000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-326000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-486000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4805000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4078000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1597000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1385000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82223000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44608000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
109908000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
85308000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
36511000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
96526000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
195000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
73202000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11218000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
83300000
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
772000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
860000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2588000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
kpti Payment Of Deferred Royalty Obligation
PaymentOfDeferredRoyaltyObligation
40518000
kpti Payment Of Deferred Royalty Obligation
PaymentOfDeferredRoyaltyObligation
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40966000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
860000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-27000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-71000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31918000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55037000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53192000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85110000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81848000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84774000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80894000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
32000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
567000
CY2024Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
304000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
387000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
85110000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81848000
us-gaap Interest Paid Net
InterestPaidNet
2933000
us-gaap Interest Paid Net
InterestPaidNet
2588000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1896000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1847000
us-gaap Payments For Royalties
PaymentsForRoyalties
16452000
us-gaap Payments For Royalties
PaymentsForRoyalties
8192000
us-gaap Stock Issued1
StockIssued1
7697000
kpti Senior Secured Term Loan Issued In Exchange Of Reduction Of Deferred Royalty Obligation
SeniorSecuredTermLoanIssuedInExchangeOfReductionOfDeferredRoyaltyObligation
14700000
us-gaap Notes Issued1
NotesIssued1
15000000
us-gaap Notes Issued1
NotesIssued1
0
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
45776213000
kpti Reduction Of Convertible Senior Notes
ReductionOfConvertibleSeniorNotes
148000000
kpti Covertible Senior Notes Issued With Warrant In Exchange Of Deferred Royalty Obligation
CovertibleSeniorNotesIssuedWithWarrantInExchangeOfDeferredRoyaltyObligation
111000000
kpti Covertible Senior Notes Issued With Warrant In Exchange Of Deferred Royalty Obligation
CovertibleSeniorNotesIssuedWithWarrantInExchangeOfDeferredRoyaltyObligation
0
kpti Convertible Senior Notes Issued In Exchange Of Reduction Of Deferred Royalty Obligation
ConvertibleSeniorNotesIssuedInExchangeOfReductionOfDeferredRoyaltyObligation
5000000
kpti Convertible Senior Notes Issued In Exchange For Deferred Royalty Obligation
ConvertibleSeniorNotesIssuedInExchangeForDeferredRoyaltyObligation
5000000
kpti Convertible Senior Notes Issued In Exchange For Deferred Royalty Obligation
ConvertibleSeniorNotesIssuedInExchangeForDeferredRoyaltyObligation
0
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-168955000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
772000
CY2024Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6928000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5410000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10000
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-77000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
23792000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-132140000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-45174000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
860000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6060000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-297000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-136206000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
772000
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
6928000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10380000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-49000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-395000
us-gaap Net Income Loss
NetIncomeLoss
-13570000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-132140000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
860000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11449000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-264000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2024Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
723000
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
553000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2155000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1732000
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
598000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
758000
CY2024Q2 us-gaap Inventory Net
InventoryNet
3476000
CY2023Q4 us-gaap Inventory Net
InventoryNet
3043000
CY2024Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
14754000
CY2023Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
9119000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
21874000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
19529000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
134010000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
169173000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
67465000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
11000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
126000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
67350000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
139281000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
96000
CY2023 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
165000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
139212000
CY2024Q2 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
35
CY2023Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
41
CY2024Q2 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2023Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
54273000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
115000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10053000
CY2024Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
11000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
64326000
CY2024Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
126000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
84465000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
152000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
6276000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
13000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
90741000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
165000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
23792000
us-gaap Net Income Loss
NetIncomeLoss
-13570000
CY2024Q2 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
5541000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
0
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
18251000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13570000
CY2024Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-30599000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-60623000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
121027000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118240000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
154425000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
127066000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5410000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6060000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10380000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11449000
CY2024Q2 kpti Debt Instrument Exchange Amount
DebtInstrumentExchangeAmount
148000000
kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
kpti Percentage Of Redemption Fee
PercentageOfRedemptionFee
0.03
CY2024Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
44702000
CY2024Q2 kpti Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
0
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-091210-index-headers.html Edgar Link pending
0000950170-24-091210-index.html Edgar Link pending
0000950170-24-091210.txt Edgar Link pending
0000950170-24-091210-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kpti-20240630.htm Edgar Link pending
kpti-20240630.xsd Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kpti-20240630_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending